SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Cognition Therapeutics, Inc. CGTX NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Cognition Therapeutics, Inc. (CGTX) is a Biotechnology company in the Healthcare sector, currently trading at $0.98. It has a SharesGrow Score of 53/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Valuation: CGTX trades at a trailing Price-to-Earnings (P/E) of -3.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.72.

Net income is $23M (loss), growing at -1169.2%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $638,000 against $34M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 3.45 (strong liquidity). Debt-to-assets is 1.3%. Total assets: $48M.

Analyst outlook: 6 / 7 analysts rate CGTX as buy (86%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 25/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 90/100 (Pass), Income ?/100 (Fail).

CGTX SharesGrow Score Overview

54/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 25/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 28/100

Gross margin is + market cap

FUTURE 90/100

Analyst outlook — as buy

INCOME 0/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CGTX

CGTX trades at a trailing Price-to-Earnings (P/E) of -3.4 (S&P 500 average ~25). Forward PEG 0.72 — Peter Lynch undervalued (≤1.0). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

CGTX: +0%/yr revenue is, -1169.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

CGTX: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet CGTX: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 3.45 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

CGTX: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.

View details →

Analyst outlook: 6 / 7 analysts rate CGTX as buy (86%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

No analyst coverage available for this stock.

Stock Chart & Stats

Market Data

52-Week Range0.222-3.83

Volume886.12K

Avg Volume (30D)1.06M

Market Cap$71.77M

Beta (1Y)1.40

Share Statistics

EPS (TTM)-0.32

Shares Outstanding$72.77M

IPO Date2021-10-08

Employees25

CEOLisa Ricciardi

Financial Highlights & Ratios

Gross Profit$-228K

EBITDA$-47.8M

Net Income$-23.49M

Operating Income$-47.8M

Total Cash$36.81M

Total Debt$638K

Net Debt$-36.17M

Total Assets$48.39M

Price / Earnings (P/E)-3

Analyst Forecast

Rating ConsensusBuy

Analysts Covering7

Buy 86% Hold 14% Sell 0%

Company Info

CountryUS

ExchangeNASDAQ Global Market

CurrencyUSD

ISINUS19243B1026

Price Chart

CGTX

Cognition Therapeutics, Inc. ↗ · NASDAQ Global Market

Healthcare • Biotechnology

0.22 52WK RANGE 3.83

People Also View

Kodiak Sciences Inc.

Day One Biopharmaceuticals, Inc.

aTyr Pharma, Inc.

Cullinan Oncology, Inc.

Autolus Therapeutics plc

Gain Therapeutics, Inc.

TScan Therapeutics, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message